Welcome to LookChem.com Sign In|Join Free

CAS

  • or

36185-83-8

Post Buying Request

36185-83-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

36185-83-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 36185-83-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,1,8 and 5 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 36185-83:
(7*3)+(6*6)+(5*1)+(4*8)+(3*5)+(2*8)+(1*3)=128
128 % 10 = 8
So 36185-83-8 is a valid CAS Registry Number.

36185-83-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name N'-(2-cyanophenyl)-N,N-dimethylmethanimidamide

1.2 Other means of identification

Product number -
Other names N'-(2-Cyanophenyl)-N,N-dimethylimidoformamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:36185-83-8 SDS

36185-83-8Relevant articles and documents

Synthesis, characterization, crystal structure, Hirshfeld interaction and bio-evaluation studies of 4-amino quinazoline sulfonamide derivatives

Sunil Kumar,Kudva, Jyothi,Madan Kumar,Vishwanatha,Kumar, Vasantha,Naral, Damodara

, p. 142 - 153 (2018)

In the present work, two new potentially active quinazolin-4-yl-aminobenzenesulfonamide derivatives, N-(5-methyl-1,2-oxazol-3-yl)-4-[(quinazolin-4-yl)amino]benzene-1-sulfonamide (4a) and N-(3,4-dimethyl-1,2-oxazol-5-yl)-4-[(quinazolin-4-yl)amino]benzene-1-sulfonamide (4b), were synthesized and the structures were confirmed by different spectroscopic techniques like FT-IR, 1H NMR, 13C NMR, HRMS and elemental analysis. The crystal structures were solved by single crystal X-ray diffraction (XRD) studies. The single crystal XRD studies revealed that the compound 4a crystallized in monoclinic crystal system in P 21/n space group with Z = 4 and compound 4b crystallized in triclinic crystal system in P-1 space group with Z = 2. The XRD study has explained the intramolecular interactions of the title compounds. The thermal behaviour was determined with the aid of differential scanning calorimetry (DSC) and thermogravimetry-differential thermal analysis (TG-DTA). Further, the Hirshfeld surface analysis with finger plots and the electrostatic potential map has shown the nature of interactions and percentage contribution from each individual intermolecular contact of these title compounds. The H?H interactions have maximum contributions and C?H, O?H and N?H also have shown major contributions to the total area of the surface. In vitro antimicrobial activity studies have disclosed that the compound 4b exhibited a moderate antibacterial activity against B. Subtilis and E. Coli strains and excellent activity against the fungal strain, A. Niger. In vitro anticancer activity of the compounds 4a and 4b was also screened against MCF 7 and MDA-MB-231 breast cancer cell lines and revealed that there is no significant effect of substitution on biological activity for the synthesized compounds.

Catalyst and solvent switched divergent C-H functionalization: Oxidative annulation of: N -aryl substituted quinazolin-4-amine with alkynes

Meesa, Siddi Ramulu,Naikawadi, Praveen Kumar,Gugulothu, Kishan,Shiva Kumar

supporting information, p. 3032 - 3037 (2020/05/08)

The development of site-selective C-H functionalizations/annulations is one of the most challenging practices in synthetic organic chemistry particularly for substrates bearing several similarly reactive C-H bonds. Herein, we describe catalyst and solvent controlled ortho/peri site-selective oxidative annulation of C-H bonds of N-aryl substituted quinazolin-4-amines with internal alkynes. The ortho C-H selective annulation was observed using Pd-catalyst in DMF to give indole-quinazoline derivatives, while, Ru-catalyst in PEG-400 favoured the peri C-H bond annulation exclusively to furnish pyrido-quinazoline derivatives.

Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient

-

Paragraph 0680; 0681; 0682, (2016/10/08)

The present invention relates to a novel compound or pharmaceutically acceptable salt thereof, and to a pharmaceutical composition containing the same as an active ingredient for treating and preventing disease caused by influenza virus infection. The novel compound represented by chemical formula 1 according to the present invention not only has extremely excellent antivirus activity, but also has less side effects for a human body by not having cytotoxicity for a human cell. Therefore, a pharmaceutical composition containing the same as an active ingredient can be used in preventing or treating such as flu, colds, sore throats, bronchitis, pneumonia, bird flu, swine flu, and goat flu caused by influenza virus infection.COPYRIGHT KIPO 2015

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 36185-83-8